Scarica l'app Stockscreener
23.99
1.28%
-0.31
Dopo l'orario di chiusura:
23.99
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Precedente Chiudi:
$24.30
Aprire:
$23.91
Volume 24 ore:
1.39M
Relative Volume:
1.39
Capitalizzazione di mercato:
$2.44B
Reddito:
-
Utile/perdita netta:
$-257.60M
Rapporto P/E:
-7.0559
EPS:
-3.4
Flusso di cassa netto:
$-220.31M
1 W Prestazione:
-6.76%
1M Prestazione:
-20.01%
6M Prestazione:
-25.93%
1 anno Prestazione:
+104.87%
Intervallo 1D:
$23.65
$24.90
Intervallo di 1 settimana:
$23.65
$26.69
Portata 52W:
$11.93
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
Nome
Dyne Therapeutics Inc
Settore
Industria
Telefono
(781) 786-8230
Indirizzo
1560 TRAPELO ROAD, WALTHAM
Confronta DYN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
23.99 | 2.44B | 0 | -257.60M | -220.31M | -3.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-10-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Reiterato | Chardan Capital Markets | Buy |
| 2024-04-30 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-20 | Iniziato | H.C. Wainwright | Buy |
| 2023-02-27 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Iniziato | Oppenheimer | Outperform |
| 2023-01-26 | Iniziato | Guggenheim | Buy |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Outperform |
| 2020-10-12 | Iniziato | JP Morgan | Overweight |
| 2020-10-12 | Iniziato | Jefferies | Buy |
| 2020-10-12 | Iniziato | Piper Sandler | Overweight |
| 2020-10-12 | Iniziato | Stifel | Buy |
Mostra tutto
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
Barclays PLC Purchases 128,246 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Wellington Management Group LLP Reduces Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Franklin Resources Inc. Cuts Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
State Street Corp Raises Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Shares Gap UpWhat's Next? - MarketBeat
Dyne Therapeutics initiated with Outperform at Baird - MSN
Dyne Therapeutics (NASDAQ:DYN) Upgraded at Raymond James - MarketBeat
How to Take Advantage of moves in (DYN) - Stock Traders Daily
Baird Initiates Coverage of Dyne Therapeutics (DYN) with Outperform Recommendation - MSN
Dyne Therapeutics (NASDAQ:DYN) Now Covered by Robert W. Baird - MarketBeat
29,694 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Acquired by Y Intercept Hong Kong Ltd - MarketBeat
DYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm! - The Eastern Progress Online
Baird sets $46 target on Dyne Therapeutics, sees upside By Investing.com - Investing.com UK
Dyne therapeutics SVP Richard Scalzo sells $40,914 in stock By Investing.com - Investing.com Nigeria
Dyne therapeutics SVP Richard Scalzo sells $40,914 in stock - Investing.com India
Dyne therapeutics' chief scientific officer sells $65,632 in stock By Investing.com - Investing.com UK
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - The Eastern Progress Online
Point72 Asset Management L.P. Sells 255,038 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
The Manufacturers Life Insurance Company Sells 20,029 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics, Inc. (NASDAQ:DYN) Position Boosted by Charles Schwab Investment Management Inc. - MarketBeat
Dyne Therapeutics (DYN) Stock Drops Amidst Biotech Sector Moveme - GuruFocus.com
Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock Holdings Boosted by RTW Investments LP - MarketBeat
RA Capital Management L.P. Grows Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $50.82 Consensus Target Price from Analysts - MarketBeat
Janus Henderson Group PLC Raises Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
HighVista Strategies LLC Makes New $2.35 Million Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Holocene Advisors LP Sells 93,712 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Piper Sandler maintains $53 target on Dyne Therapeutics stock By Investing.com - Investing.com Canada
Fmr LLC Has $324.24 Million Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Shares Down 4.2%Time to Sell? - MarketBeat
Eventide Asset Management LLC Sells 152,723 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Intech Investment Management LLC Purchases New Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Myotonic dystrophy pipeline shows momentum - The Pharma Letter
Acuta Capital Partners LLC Sells 166,300 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Myotonic Dystrophy Clinical Trial Pipeline Boom as Over 20 Companies Leading the Charge in Research and Development | DelveInsight - The Malaysian Reserve
Connor Clark & Lunn Investment Management Ltd. Invests $1.48 Million in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Victory Capital Management Inc. Purchases 11,385 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne, Avidity initiated at outperform by RBC on DM1 drugs (NASDAQ:DYN) - Seeking Alpha
Dyne Therapeutics (NASDAQ:DYN) Coverage Initiated at Royal Bank of Canada - MarketBeat
RBC Capital starts Dyne Therapeutics shares at Outperform, targets genetic medicine success - Investing.com UK
Principal Financial Group Inc. Reduces Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Susanna High named CEO of Paragon - BioCentury
Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts - Insider Monkey
Jennison Associates LLC Has $48.38 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
DYN (Dyne Therapeutics) 9-Day RSI : 49.47 (As of Nov. 21, 2024) - GuruFocus.com
Dyne Therapeutics director Incerti Carlo sells $474,045 in stock - Investing.com India
Dyne Therapeutics Inc Azioni (DYN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dyne Therapeutics Inc Azioni (DYN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Scalzo Richard William | SVP, Head of Finance & Admin. |
Dec 11 '24 |
Sale |
28.12 |
1,455 |
40,915 |
127,078 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):